Influenza A virus H5N1 vaccine - Novavax

Drug Profile

Influenza A virus H5N1 vaccine - Novavax

Alternative Names: H5N1 Clade 2 VLP influenza virus vaccine - Novavax; H5N1 Virus-Like Particle (VLP) Influenza vaccine (recombinant) - Novavax; H5N1 virus-like particle pandemic influenza vaccine - Novavax

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Novavax
  • Developer Novavax; University of Hong Kong
  • Class Influenza A virus H5N1 vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in Hong Kong (IM, Injection)
  • 23 Sep 2014 BARDA modifies its contract with Novavax and awards an option period for Influenza-A virus H5N1 subtype vaccine development until September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top